COPD: Review of Current Treatment Guidelines

Chronic Obstructive Pulmonary Disease (COPD) is a progressive yet preventable and treatable condition marked by persistent respiratory symptoms and airflow limitation. It remains a leading cause of chronic morbidity and mortality worldwide, largely due to exposure to harmful particles or gases, most notably tobacco smoke.

This 1-hour CME/CE course provides healthcare professionals with an evidence-based approach to the pharmacological management of COPD. Participants will learn how to evaluate disease severity using validated assessment tools, differentiate between pharmacologic classes used in treatment, and develop individualized treatment regimens. The course also includes a review of the most up-to-date clinical guidelines to support sound therapeutic decision-making.

Designed for primary care physicians, pulmonologists, nurse practitioners, and physician assistants, this course strengthens clinical competency in optimizing outcomes for patients with COPD.

Educational Objectives

• Examine pharmacological assessment tools used in the diagnosis and staging of COPD.
• Cite the various pharmacotherapeutic options for treating COPD.
• Design a therapy regimen for patients who continue to experience symptoms or exacerbations after initial treatment.
• Apply evidence-based guidelines in making pharmacotherapeutic decisions for managing COPD.

Who Should Take This Course

This course is recommended for:

• Physicians, Nurse Practitioners, and Physician Assistants who diagnose or manage patients with chronic respiratory conditions.
• Pulmonologists and respiratory therapists seeking updated guidance on pharmacologic interventions.
• Primary care providers managing patients at risk for or living with COPD.
• Clinicians looking to align their practice with the latest COPD treatment guidelines.

Did You Know?

• COPD is the third leading cause of death worldwide, responsible for over 3 million deaths annually. [WHO, 2023]
• More than 16 million Americans have been diagnosed with COPD, with millions more likely undiagnosed. [CDC, 2022]
• Long-acting bronchodilators are the mainstay of COPD maintenance therapy. [GOLD, 2023]
• Smoking cessation is the most effective intervention to slow disease progression. [NIH, 2021]
• Early identification and treatment of exacerbations significantly reduce hospitalizations and improve quality of life. [BMJ, 2020]